2025
SJR Q1
JCR Q1 · 6,4
OA
432 eşleşen makale
SCIE
Dergi ayrıntısı
Life Sciences
- Yayıncı
- Elsevier Inc.
- Ülke
- United States · Northern America
- Tür
- journal
- ISSN
-
0024320518790631
Bütünleşik değerlendirme
Scopus tarafı Scimago SJR; WoS tarafı Master Journal List + JCR/JIF. Kaynaklar ISSN üzerinden eşleştirilir. WoS / JCR metrikleri yalnızca 1997 ve sonrası yıllar için vardır.
WoS / JCR verileri 1997 ve sonrası içindir.
Scopus
Scopus · Scimago
- SJR 1,487
- Quartile Q1
- H-Index 211
- Atıf/yayın 6,52
- Doküman (3y) 2.358
- Atıf (3y) 15.153
Clarivate
Web of Science · JCR · 2025
- JCR Q Q1
- JIF 6,4
- 5Y JIF 5,9
- JCI 1,39
WoS indeksleri
- SCIE
Konu sınıflandırması
Kategoriler (SJR)
- Biochemistry, Genetics and Molecular Biology (miscellaneous) Q1
- Medicine (miscellaneous) Q1
- Pharmacology, Toxicology and Pharmaceutics (miscellaneous) Q1
Alanlar
- Biochemistry, Genetics and Molecular Biology
- Medicine
- Pharmacology, Toxicology and Pharmaceutics
WoS kategorileri
- Medicine, Research & Experimental | Pharmacology & Pharmacy
Yıllık quartile karşılaştırması
Scimago (SJR) tüm yıllar; Clarivate (JCR / JIF / JCI) 1997 ve sonrası. Güncel yıl açık; diğer yıllar kapalıdır.
WoS / JCR verileri 1997 ve sonrası içindir.
| Yıl | SJR Q | JCR Q (1997+) | SJR | JIF (1997+) | 5Y JIF (1997+) | JCI (1997+) | JCI Q (1997+) | H-Index |
|---|---|---|---|---|---|---|---|---|
| 2025 | Q1 | Q1 | 1,487 | 6,4 | 5,9 | 1,39 | Q1 | 211 |
| 2024 | Q1 | Q1 | 1,315 | 5,1 | 5,4 | 1,33 | Q1 | 200 |
| 2023 | Q1 | Q1 | 1,257 | 5,2 | 5,3 | 1,39 | Q1 | 200 |
| 2022 | Q1 | Q1 | 1,207 | 6,1 | 5,8 | 1,43 | Q1 | 200 |
| 2021 | Q1 | Q1 | 1,132 | 6,8 | 6 | 1,41 | Q1 | 200 |
| 2020 | Q1 | Q1 | 1,131 | 5 | 4,7 | 1,21 | Q1 | 200 |
| 2019 | Q1 | Q2 | 1,031 | 3,6 | 3,4 | 1,19 | Q1 | 200 |
| 2018 | — | Q2 | — | 3,4 | 3,2 | 1,13 | Q1 | — |
| 2017 | Q1 | Q2 | 1,071 | 3,2 | 2,9 | 1,11 | Q1 | 200 |
| 2016 | Q1 | Q2 | 1,093 | 2,9 | 2,7 | — | — | 200 |
| 2015 | Q1 | Q2 | 1,066 | 2,7 | 2,6 | — | — | 200 |
| 2014 | Q1 | Q2 | 1,074 | 2,7 | 2,7 | — | — | 200 |
| 2013 | Q1 | Q2 | 0,968 | 2,3 | 2,5 | — | — | 200 |
| 2012 | Q1 | Q2 | 0,906 | 2,6 | 2,7 | — | — | 200 |
| 2011 | Q1 | Q2 | 1,014 | 2,5 | 2,7 | — | — | 200 |
| 2010 | Q1 | Q2 | 1,009 | 2,5 | 2,7 | — | — | 200 |
| 2009 | — | Q2 | — | 2,6 | 2,7 | — | — | — |
| 2008 | — | Q2 | — | 2,6 | 2,6 | — | — | — |
| 2007 | — | Q2 | — | 2,3 | 2,4 | — | — | — |
| 2006 | — | Q2 | — | 2,4 | — | — | — | — |
| 2005 | — | Q2 | — | 2,5 | — | — | — | — |
| 2004 | — | Q2 | — | 2,2 | — | — | — | — |
| 2003 | — | Q2 | — | 1,9 | — | — | — | — |
| 2002 | — | Q2 | — | 1,8 | — | — | — | — |
| 2001 | — | Q2 | — | 1,8 | — | — | — | — |
| 2000 | — | Q2 | — | 1,8 | — | — | — | — |
| 1999 | — | Q2 | — | 1,8 | — | — | — | — |
| 1998 | — | Q1 | — | 1,9 | — | — | — | — |
| 1997 | — | Q1 | — | 2,3 | — | — | — | — |
JCR kategori quartile geçmişi
Yıla ve kategoriye göre JCR / JCI quartile. 1997 ve sonrası.
WoS / JCR verileri 1997 ve sonrası içindir.
| Yıl | Kategori | Edition | JCR Q (1997+) | JCI Q (1997+) | Sıra |
|---|---|---|---|---|---|
| 2025 | MEDICINE, RESEARCH & EXPERIMENTAL | SCIE | Q1 | Q1 | 39/191 |
| 2025 | PHARMACOLOGY & PHARMACY | SCIE | Q1 | Q1 | 42/356 |
| 2024 | MEDICINE, RESEARCH & EXPERIMENTAL | SCIE | Q1 | Q1 | 44/195 |
| 2024 | PHARMACOLOGY & PHARMACY | SCIE | Q1 | Q1 | 44/352 |
| 2023 | MEDICINE, RESEARCH & EXPERIMENTAL | SCIE | Q1 | Q1 | 39/189 |
| 2023 | PHARMACOLOGY & PHARMACY | SCIE | Q1 | Q1 | 40/354 |
| 2022 | MEDICINE, RESEARCH & EXPERIMENTAL | SCIE | Q1 | Q1 | 33/136 |
| 2022 | PHARMACOLOGY & PHARMACY | SCIE | Q1 | Q1 | 34/278 |
| 2021 | MEDICINE, RESEARCH & EXPERIMENTAL | SCIE | Q1 | Q1 | 33/139 |
| 2021 | PHARMACOLOGY & PHARMACY | SCIE | Q1 | Q1 | 36/279 |
| 2020 | MEDICINE, RESEARCH & EXPERIMENTAL | SCIE | Q2 | Q1 | 46/140 |
| 2020 | PHARMACOLOGY & PHARMACY | SCIE | Q1 | Q1 | 65/276 |
| 2019 | MEDICINE, RESEARCH & EXPERIMENTAL | SCIE | Q2 | Q1 | 56/139 |
| 2019 | PHARMACOLOGY & PHARMACY | SCIE | Q2 | Q1 | 76/271 |
| 2018 | MEDICINE, RESEARCH & EXPERIMENTAL | SCIE | Q2 | Q1 | 56/136 |
| 2018 | PHARMACOLOGY & PHARMACY | SCIE | Q2 | Q1 | 76/267 |
| 2017 | MEDICINE, RESEARCH & EXPERIMENTAL | SCIE | Q2 | Q1 | 53/133 |
| 2017 | PHARMACOLOGY & PHARMACY | SCIE | Q2 | Q1 | 78/261 |
| 2016 | MEDICINE, RESEARCH & EXPERIMENTAL | SCIE | Q2 | — | 45/128 |
| 2016 | PHARMACOLOGY & PHARMACY | SCIE | Q2 | — | 94/257 |
| 2015 | MEDICINE, RESEARCH & EXPERIMENTAL | SCIE | Q2 | — | 53/124 |
| 2015 | PHARMACOLOGY & PHARMACY | SCIE | Q2 | — | 96/255 |
| 2014 | MEDICINE, RESEARCH & EXPERIMENTAL | SCIE | Q2 | — | 53/123 |
| 2014 | PHARMACOLOGY & PHARMACY | SCIE | Q2 | — | 103/255 |
| 2013 | MEDICINE, RESEARCH & EXPERIMENTAL | SCIE | Q2 | — | 60/124 |
| 2013 | PHARMACOLOGY & PHARMACY | SCIE | Q2 | — | 124/256 |
| 2012 | MEDICINE, RESEARCH & EXPERIMENTAL | SCIE | Q2 | — | 55/121 |
| 2012 | PHARMACOLOGY & PHARMACY | SCIE | Q2 | — | 107/261 |
| 2011 | MEDICINE, RESEARCH & EXPERIMENTAL | SCIE | Q2 | — | 47/112 |
| 2011 | PHARMACOLOGY & PHARMACY | SCIE | Q2 | — | 107/261 |
| 2010 | MEDICINE, RESEARCH & EXPERIMENTAL | SCIE | Q2 | — | 42/106 |
| 2010 | PHARMACOLOGY & PHARMACY | SCIE | Q2 | — | 115/252 |
| 2009 | MEDICINE, RESEARCH & EXPERIMENTAL | SCIE | Q2 | — | 36/93 |
| 2009 | PHARMACOLOGY & PHARMACY | SCIE | Q2 | — | 103/237 |
| 2008 | MEDICINE, RESEARCH & EXPERIMENTAL | SCIE | Q2 | — | 33/83 |
| 2008 | PHARMACOLOGY & PHARMACY | SCIE | Q2 | — | 89/219 |
| 2007 | MEDICINE, RESEARCH & EXPERIMENTAL | SCIE | Q2 | — | 33/81 |
| 2007 | PHARMACOLOGY & PHARMACY | SCIE | Q2 | — | 96/205 |
| 2006 | MEDICINE, RESEARCH & EXPERIMENTAL | SCIE | Q2 | — | 28/76 |
| 2006 | PHARMACOLOGY & PHARMACY | SCIE | Q2 | — | 79/199 |
| 2005 | MEDICINE, RESEARCH & EXPERIMENTAL | SCIE | Q2 | — | 28/72 |
| 2005 | PHARMACOLOGY & PHARMACY | SCIE | Q2 | — | 62/193 |
| 2004 | MEDICINE, RESEARCH & EXPERIMENTAL | SCIE | Q2 | — | 26/71 |
| 2004 | PHARMACOLOGY & PHARMACY | SCIE | Q2 | — | 69/187 |
| 2003 | MEDICINE, RESEARCH & EXPERIMENTAL | SCIE | Q2 | — | 32/72 |
| 2003 | PHARMACOLOGY & PHARMACY | SCIE | Q2 | — | 77/185 |
| 2002 | MEDICINE, RESEARCH & EXPERIMENTAL | SCIE | Q2 | — | 33/74 |
| 2002 | PHARMACOLOGY & PHARMACY | SCIE | Q2 | — | 74/188 |
| 2001 | BIOLOGY | SCIE | Q2 | — | 12/42 |
| 2001 | MEDICINE, RESEARCH & EXPERIMENTAL | SCIE | Q2 | — | 30/75 |
| 2001 | PHARMACOLOGY & PHARMACY | SCIE | Q2 | — | 63/186 |
| 2000 | BIOLOGY | SCIE | Q2 | — | 16/51 |
| 2000 | MEDICINE, RESEARCH & EXPERIMENTAL | SCIE | Q2 | — | 30/74 |
| 2000 | PHARMACOLOGY & PHARMACY | SCIE | Q2 | — | 63/181 |
| 1999 | BIOLOGY | SCIE | Q2 | — | 16/53 |
| 1999 | MEDICINE, RESEARCH & EXPERIMENTAL | SCIE | Q2 | — | 27/76 |
| 1999 | PHARMACOLOGY & PHARMACY | SCIE | Q2 | — | 58/175 |
| 1998 | BIOLOGY | SCIE | Q2 | — | 17/66 |
| 1998 | MEDICINE, RESEARCH & EXPERIMENTAL | SCIE | Q2 | — | 21/72 |
| 1998 | PHARMACOLOGY & PHARMACY | SCIE | Q1 | — | 36/178 |
| 1997 | BIOLOGY | SCIE | Q1 | — | 10/63 |
| 1997 | MEDICINE, RESEARCH & EXPERIMENTAL | SCIE | Q1 | — | 13/61 |
| 1997 | PHARMACOLOGY & PHARMACY | SCIE | Q1 | — | 29/157 |